IJBPAS, October, 2026, 15(10): 4861-4871

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

EXPLORING REGULATORY HURDLES IN NUTRACEUTICALS AND THE IMPACT OF NANOFORMULATIONS

KHANDOMALKE V.R[1], YELMATE A.A[2] AND SATPUTE K.L[3*]

1: PG Student, Department of Regulatory Affairs, Dayanand College of Pharmacy, Latur, Maharashtra,413512 India

2: Assistant Professor, Department of Pharmaceutics, Dayanand College of Pharmacy, Latur, Maharashtra,413512 India

***Corresponding Author: Ms. Khandomalke Vaishnavi Ramesh: E Mail: vaishnavikhandomalke@gmail.com**

Received 20th Dec. 2025; Revised 25th Jan. 2026; Accepted 10th May 2026; Available online 1st Oct. 2026

https://doi.org/10.31032/IJBPAS/2026/15.10.10525

ABSTRACT

Nutraceuticals, such as functional foods, dietary supplements, and therapeutic foods, are crucial for fostering health and averting illness. However, a number of nutraceutical bioactive chemicals' quick metabolism, low bioavailability, poor stability, and poor water solubility limit their therapeutic efficacy. Because nanoformulation techniques enhance the bioavailability, stability, controlled release, and targeted administration of nutraceutical components, they have become a viable means of overcoming these constraints. In this assessment, the regulatory environment around nutraceuticals is critically examined, with a focus on goods that are enabled by nanotechnology. Significant regulatory obstacles include the lack of agreed-upon terminology, ambiguity in the classification of food and medication categories, issues in verifying health claims, inconsistent labeling standards, and post-market surveillance constraints. We address common nanoencapsulation technologies utilized in nutraceuticals, including polymer-based systems, solid lipid nanoparticles, liposomes, and nanosuspensions, utilizing omega-3 fatty acids, curcumin, and coenzyme Q10 as sample examples. Concerns about long-term safety, toxicity specific to nanoparticles, and irregularities in analytical and regulatory evaluation techniques persist despite the substantial functional benefits that nanoformulations provide. For the development of nano-nutraceuticals to be safe and successful, the review emphasizes the necessity of strong scientific evidence and standardized international regulatory frameworks.

Keywords: Nutraceuticals; Nanoformulation; Regulatory challenges; Bioavailability; Safety

1. INTRODUCTION

1.1 The definition of Nutraceuticals

Nutraceuticals are food-based products that offer health advantages beyond simple nourishment and may help prevent illness or promote good health. The phrase was created by Stephen DeFelice to characterize the intersection of drugs and nutrition **[1]**.

When included in a regular diet, functional foods are traditional foods enhanced with physiologically active substances that provide additional physiological or health benefits beyond their nutritional worth **[2]**.

Dietary supplements, which come in liquid, powder, tablet, or capsule form, are products that are taken orally and contain vitamins, minerals, herbs, or other bioactive ingredients. Their purpose is to supplement the regular diet **[3]**.

1.2 Market Growth & Importance

Advances in food science and research are supporting the growing consumer desire for natural, diet-based methods to disease prevention and health promotion, which is driving the nutraceutical market's rapid expansion **[5–8]**. Regulatory complexity, uneven product quality, and issues with labeling and health claim verification limit market expansion despite their acknowledged biological benefits. Standardized testing, thorough scientific research, and more transparent regulatory frameworks are needed to address these problems and guarantee product efficacy, safety, and broader market acceptance **[9–12]**.

2. The Nutraceuticals Regulatory Environment

2.1 Regulating bodies in various nations' nutraceutical industries.

Major markets' regulatory agencies guarantee the safety, efficacy, and constant quality of nutraceuticals:

- **USA:** The Dietary Supplement Health and Education Act (DSHEA, 1994) governs nutraceuticals as dietary supplements rather than medications. Manufacturers must guarantee safety and correct labeling, but pre-market approval is typically not needed unless ingredients are novel **[14]**.
- **The European Food Safety Authority (EFSA)** regulates nutraceuticals as dietary supplements. Scientific validation is necessary for health claims, and depending on the claim, pre-market permission can be required **[15]**.
- **India-FSSAI**: In accordance with general food law, India controls nutraceuticals. Because there isn't a legally separate category for nutraceuticals, they are classified similarly to dietary supplements and functional foods **[16]**.

2.2 Classification Challenges

Table 1: Borderline products between food, supplements and drugs

Challenge	Description	Example Regulatory Issue
Terminology ambiguity [17]	Nutraceutical" lacks a global legal definition; overlaps with foods, supplements, and drugs	Products may be treated as food in one country and drug in another, causing compliance issues
Food/supplement vs drug overlap [18]	Same ingredient may fall under different categories based on use or claims	High-dose botanicals or melatonin may be regulated as drugs in some regions
Differing regulatory frameworks	Regulations vary across countries; some require stricter evidence or quality checks	US (DSHEA) treats as supplements, EU may demand more proof for functional foods

Table 2: Labelling and claims ambiguity

Challenge	Description	Example Regulatory Issue
Health vs therapeutic claims [14]	Distinguishing general wellness from disease-specific claims.	Disease claims can reclassify a food/supplement as a drug.
Global Variation [19]	Inconsistent approval systems across different regions.	EU requires pre-approval; FDA allows structure/function claims
Misleading Labels [14]	Weak premarket reviews lead to unsupported marketing.	Conflict between marketing hype and scientific proof.
Consumer perception issues [19]	Ambiguous language blurs the line between food and medicine.	Lack of standard terms causes cross-market confusion.

2.3. GMP and Pharmacopeial Standards in Nutraceuticals

Safety issues, GMP, and quality control in nutraceuticals

When the nutraceuticals are put out in the market without a pre-market efficacy evaluation requirement, a regulatory loophole occurs between foods and drugs. This gap has often led to wide differences in the quality of the products and false medicine claims that lacked support. The absence of internationally accepted quality standards further complicates international trade and regulatory monitoring because it is difficult to ensure consistency in the level of control at all regions.

Good Manufacturing Practices (GMP) form a fundamental foundation to maintain the quality of a product but at least, significant variations in constituent quantity, purity, and strength of the labelled and actual products are observed. The systematic threats of contamination and adulteration present the urgent need of stricter regulatory monitoring and regular testing protocols and universally standardized quality benchmarks to ensure the reliability and safety of products **[14, 20-23]**.

3. Regulations Concerning Nutraceuticals: Obstacles

3.1 Insufficient International Coherence

Regulations governing nutraceuticals differ greatly between nations, making it difficult to enter international markets. While several jurisdictions have more stringent notice or registration requirements, others need pre-market approval with copious documentation. Market access is delayed,

compliance costs are raised, and the need for more uniform worldwide approval requirements is highlighted by this regulatory fragmentation **[24, 41]**.

3.2 Scientific Evidence and Efficacy

Regulatory bodies need strong scientific proof to back up nutraceutical health claims, and human clinical data is thought to be the most trustworthy. Many claims are not authorized because they mostly rely on in vitro or animal studies instead of carefully planned human trials. The ability of randomized clinical trials to prove causation makes them the gold standard for proving efficacy, whereas observational studies offer helpful real-world insights but are more susceptible to bias and confounding. Collectively, these results demonstrate that comprehensive human clinical proof is required before nutraceutical health claims may be approved **[25,26]**.

3.3 Monitoring After the Market

Due to lack of pre-market evidence, post-market monitoring is crucial in the assurance of safety of nutraceutical products. Though such adverse event reporting practices contribute to the detection of potential safety signals, under-reporting remains a rather serious limitation, which supports the need to have more credible and structured nutrivigilance systems **[27, 42]**. Efficient product recall and traceability systems enhance consumer protection, legal compliance and public trust because harmful products are easily detected and recalled **[28]**.

The process of acquiring patent protection of nutraceuticals is very hard since most of the bioactive chemicals present in nature are considered to fall into the category of the public domain and lack the originality required to have intellectual property rights. Similarly, although nanoformulation technologies have numerous advantages, they are associated with complex the issues of patentability and regulations that restrict successful intellectual property protection and can discourage the development of nano-nutraceuticals. The use of nanoformulations in diet supplements.

4.1 Nutraceutical nanoencapsulation technology

To increase the stability, bioavailability, and regulated distribution of bioactive compounds especially those with low solubility or degradation susceptibility nanoencapsulation technologies are being used more and more in nutraceutical formulations. Today, regulatory and translational attention is focused on how various nanocarrier systems affect the safety, effectiveness, and quality control of nutraceutical products rather than formulation procedures **[29–30]**.

Liposomes are phospholipid vesicles that contain hydrophilic and lipophilic chemicals, increasing membrane permeability and stability; nevertheless,

their loading capacity and cost are restricted **[29]**.

Polymer-Based Systems: Biodegradable polymers, such as PLGA, alginate, and chitosan, allow for adjustable release and protect bioactives; they are safe and adaptable for use in food applications **[13]**.

4.2 Advantages of Nanoformulations.

• **Better Bioavailability:** By enhancing dissolving, absorption, and protection against premature metabolism, nanoformulations improve the oral bioavailability of nutraceuticals with poor solubility.

• **Improved Stability:** By shielding delicate nutraceuticals from physiological and environmental deterioration (such as oxidative stress, enzymatic breakdown, and pH changes), encapsulation extends their shelf life and maintains their functional integrity. therapeutic efficacy while reducing systemic toxicity and off-target effects.

Table 3: Representative nutraceuticals utilizing nano-based delivery systems

Compound	limitation	Nano approach used	Observed benefit
Curcumin	Very low water solubility and poor oral bioavailability	Nano-emulsions, polymeric nanoparticles, liposomes	Enhanced bioavailability, stability, and antioxidant activity. [32,33]
Coenzyme Q10 (CoQ10)	Lipophilic nature leading to poor absorption from conventional formulations	Nano-dispersions, micellar systems, lipid-based nanocarriers	Increased absorption, sustained release, and degradation protection release.[32,34]
Omega-3 fatty acids (EPA, DHA)	Susceptibility to oxidation and low aqueous solubility	Nano-emulsions, lipid nanoparticles, nanostructured lipid carriers	Increased oxidative stability, shelf-life, and digestive uptake.[34]

5. The Effect of Nanoformulations on Food and Nutraceuticals Regulation.

5.1 Definitions and Guidelines

Generally speaking, according to ISO and IUPAC standards, materials that have at least one dimension in the nanoscale (~1–100 nm) are considered nanomaterials in food and nutraceuticals **[35]**. Intentionally created materials with nanoscale characteristics, such as aggregates, are categorized as engineered nanomaterials that need a pre-market safety evaluation under the EU Novel Food Regulation **[40]**. Because of gastrointestinal absorption, several authorities deem particles up to 250 nm important for risk assessment **[36]**.

5.2 Safety and Toxicological Aspects

When compared to their traditional forms, there is the ability to alter the absorption, distribution, metabolism, and excretion (ADME) of bioactive substances in their nanoformulations **[37].** Although there is a common consensus that most lipid- or protein-based nanocarriers are degraded into non-toxic substances in the gastrointestinal tract, very little kinetic data is available on

how to absorb the systemically and on long-term human exposure.

Nanotechnology effects such as cellular absorption, inflammation and effects on the gut flora can be too insidious to analyze using toxicity studies. The latest toxicological studies also indicate deficiencies in the evaluation of low dose and chronic exposures scenarios **[13,31].** Due to the possible risks that are oxidative stress, inflammatory responses, greater intestinal permeability, and broader organ distribution, precautionary regulatory actions have been established **[31, 37].**

5.3 Difficulties with Labeling and Regulatory Analysis

To evaluate size, shape, and surface characteristics, characterization techniques like X-ray scattering, electron microscopy (TEM/SEM), zeta potential, dynamic light scattering (DLS), and nanoparticle tracking analysis (NTA) are employed **[4]**. Regulatory compliance is complicated by the lack of globally standardized requirements for nanomaterials in complex food matrices. Although there is still a lack of consistency in labeling and reporting standards, the EU requires disclosure of nanoforms, while other countries (such as India through the FSSAI) demand risk assessments and safety dossiers **[13]**.

5.4 US, EU, and Indian regulatory perspectives

- **USA:** Food nanotechnology is evaluated according to current laws based on product specificity (FDA & GRAS). Early FDA consultation is advised since GRAS determinations for purposefully manufactured nanomaterials are limited due to a lack of safety data **[38]**.
- Engineered nanomaterials are regarded as new foods under **EU** (EFSA & new Food Regulation) regulations, which call for pre-market approval, clear labelling, and risk assessment taking into account nanospecific characteristics **[39]**.
- **India (FSSAI):** Manufacturers must demonstrate the safety of nanomaterials, which are governed by both contemporary food additive and new food frameworks. Harmonized rules tailored to nanotechnology are still being developed, and case-by-case evaluations are used **[40]**.

6. Regulatory Views on Nutraceuticals and Food Nanoforms

6.1 USA: GRAS & FDA

Although the FDA lacks a specific legal definition of nanotechnology, it does classify items that contain nanoscale materials (≈1–100 nm) or have features that are dependent on nanoscale as incorporating nanotechnology. Regulatory control is based

on research and products, not on laws that are particular to nanotechnology, but rather on existing regulations for foods, supplements, medications, or devices. When safety data is scarce, companies are advised to seek early FDA consultation **[40]**. At the moment, no designed nanoscale food ingredient satisfies the requirements for formal GRAS affirmation due to the lack of appropriate safety proof. Although there are no GRAS rules unique to nanotechnology, voluntary GRAS notifications are feasible **[38]**.

6.2 Novel Food Regulation and the European Union's EFSA

Regarding nanoparticles in food and feed, EFSA offers guidelines for physicochemical characterisation, toxicological testing, exposure evaluation, and hazard identification. Tiered, nanospecific risk assessment is the focus of updated advice (2021) **[39]**.

CONCLUSION

Nutraceuticals are crucial for promoting health, but their development is constrained by unclear regulations, inconsistent quality, and a lack of solid clinical data. Effective ways to increase the bioavailability, stability, and delivery of nutraceutical bioactives are provided by nanoformulation techniques. However, there are new difficulties with safety assessment, characterisation, and labelling that come with items that are enabled by nanotechnology. There is uneven oversight as a result of current regulatory frameworks' heavy reliance on pre-existing food and supplement rules. To guarantee the safe and efficient development of nano-nutraceuticals, standardized analytical techniques, uniform rules, and thorough safety evaluation are necessary.

REFERENCES

[1] Tamboli FA, Waghmare RS, Gajewar SR, Gavhane DG, Disale PP, Jogi PR, *et al*. Nano nutraceuticals: revolutionizing the future of health supplements. Biomed Pharmacol J. 2025;18(1):459–70. doi: 10.13005/bpj/3100

[2] Arshad Z, Shahid S, Hasnain A, Yaseen E, Rahimi M. Functional foods enriched with bioactive compounds: therapeutic potential and technological innovations. Food Science Nutrition 2025;13(10). doi: 10.1002/fsn3.71024.

[3] U.S. Food and Drug Administration. Dietary supplements [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 Feb 10]. Available from: https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements

[4] Holmes JL, Biella A, Morck T, Rostorfer J, Schneeman B. Supplements and symposia: food and nutrition policy. J Nutr. 2001;131(3):1118S-21S. doi: 10.1093/jn/131.3.1118S.

[5] Nasri H, Baradaran A, Shirzad H, Rafieian-Kopaei M. New concepts in nutraceuticals as alternative for pharmaceuticals. Int J Prev Med. 2014 Dec;5(12):1487–99.

[6] Makkar R, Behl T, Bungau S, Zengin G, Mehta V, Kumar A, *et al*. Nutraceuticals in neurological disorders. Int J Mol Sci. 2020 Jun 22;21(12):4424. doi: 10.3390/ijms21124424.

[7] Yahfoufi N, Alsadi N, Jambi M, Matar C. The immunomodulatory and anti-inflammatory role of polyphenols. Nutrients. 2018 Nov 2;10(11):1618. doi: 10.3390/nu10111618.

[8] Clarke JO, Mullin GE. A review of complementary and alternative approaches to immunomodulation. Nutrition in Clinical Practice 2008 Feb;23(1):49–62. doi: 10.1177/011542650802300149.

[9] Biesalski HK, Aggett PJ, Anton R, Bernstein PS, Blumberg J, Heaney RP, *et al*. 26th Hohenheim Consensus Conference, September 11, 2010 Scientific substantiation of health claims: evidence based nutrition. Nutrition. 2011 Oct 1;27(10): S1–20. doi: 10.1016/j.nut.2011.07.017.

[10] Manikandaselvi S, Vadivel V, Brindha P. Nutraceuticals: an overview. Int J Pharm Bio Sci. 2016;7(1):284–96.

[11] Parasuram Rajam R, Murugesan G, Vadivelkumar K, Menachisundaram V. Nutraceuticals: a review. World J Pharm Res. 2019;8(11):1354–65. doi: 10.20959/wjpr201911-15964.

[12] Dhotre H, Bhagwat R, Modak B, Ghare A, Kale M. An extensive review article on nutraceuticals. Int J Creat Res Thoughts. 2024;12(2):b527–b533.

[13] Mehta J, Pathania K, Pawar SV. Recent overview of nanotechnology based approaches for targeted delivery of nutraceuticals. Sustain Food Technol. 2025;3(4):947–78. doi: 10.1039/d5fb00122f.

[14] Komala MG, Ong SG, Qadri MU, Elshafie LM, Pollock CA, Saad S. Investigating the regulatory process, safety, efficacy and product transparency for nutraceuticals in the USA, Europe and Australia. Foods. 2023;12(2):427. doi: 10.3390/foods12020427.

[15] European Food Safety Authority. Food supplements [Internet]. Parma: EFSA; c2026 [cited 2026 Feb 10]. Available from: https://www.efsa.europa.eu/en/topics/topic/food-supplements

[16] Ramdasi V, Lingala D, Macharam K, Saxena T, Prasanthi D. Nutraceutical regulations in India: a comprehensive review. Int J Drug Regulat Affairs. 2023;11(3):80–6. doi: 10.22270/ijdra.v11i3.626.

[17] Rani A, Kumar Shukla V. Study of nutraceutical regulations around the globe. Int J Drug Regulat Affairs. 2020;8(1):15–24. doi: 10.22270/ijdra.v8i1.378.

[18] Food Safety Institute. Navigating the regulations of nutraceuticals in India [Internet]. [place unknown]: Food Safety Institute; 2025 Apr 14 [cited 2026 Feb 10]. Available from: https://foodsafety.institute/emerging-trends-food-technology-safety/navigating-nutraceutical-regulations-india/

[19] Fekete M, Lehoczki A, Kryczyk-Poprawa A, Zábó V, Varga JT, Bálint M, *et al*. Functional foods in modern nutrition science: mechanisms, evidence, and public health implications. Nutrients. 2025;17(13):2153. doi: 10.3390/nu17132153.

[20] Radheshyam. A review on: nutraceuticals challenges in formulation and its regulatory aspects. J Pharm Res [Internet]. [date unknown]; [cited 2026 Feb 10]. Available from: https://www.opastonline.com/

[21] Patil S, Baheti B. A review on good manufacturing practice. Int J Pharm Res Dev. 2025;7(2):637–43. doi: 10.33545/26646862.2025.v7.i2g.229.

[22] Lockwood GB. The quality of commercially available nutraceutical supplements and food sources. J Pharm Pharmacol. 2011;63(1):3–10. doi: 10.1111/j.2042-7158.2010.01159.x.

[23] Alali M, Alqubaisy M, Aljaafari MN, Alali AO, Baqais L, Molouki A, *et al*. Nutraceuticals: transformation of conventional foods into health promoters/disease preventers and safety considerations. Molecules. 2021;26(9):2540. doi: 10.3390/molecules26092540.

[24] Fathimabeevi NS, Panneerselvam C, Maanvizhi S. Comparison and registration pathway of nutraceuticals in Canada, Australia and South Korea. Int J Drug Regulat Affairs. 2025;13(4):19–25. doi: 10.22270/ijdra.v13i4.813.

[25] Ashwell M, Hickson M, Stanner S, Prentice A, Williams CM. Nature of the evidence base and strengths, challenges and recommendations in the area of nutrition and health claims: a position paper from the Academy of Nutrition Sciences. Br J Nutr. 2023;130(2):221–38. doi: 10.1017/S0007114522003300.

[26] Grant WB, Boucher BJ, al Anouti F, Pilz S. Comparing the evidence from observational studies and randomized controlled trials for nonskeletal health effects of Vitamin D. Nutrients. 2022;14(18):3811. doi: 10.3390/nu14183811.

[27] Luthra VR, Toklu HZ. Nutrivigilance: the road less traveled. Front Pharmacol. 2023;14:1274810. doi: 10.3389/fphar.2023.1274810.

[28] Pulita JG, Canesin H, Oliveira LL, Silva AL, Pereira CR. The role of traceability in food recall management: a systematic literature review. GePROS. 2022;17(2):86. doi: 10.15675/gepros.v17i2.2881.

[29] Memon AB, Naz Z, Khan MZ, Shah AA. Nanoencapsulation of nutraceuticals for enhanced bioavailability. Multidiscip Surg Res Ann. [date unknown]; [cited 2026 Feb 10]. Available from: https://msrajournal.com/

[30] Gul S, Miano TF, Mujeeb A, Chachar M, Majeedano MI, Murtaza G, *et al*. Advancements in nutraceutical delivery: integrating nanotechnology and microencapsulation for enhanced efficacy and bioavailability. Matrix Sci Pharma. 2024;8(1):1–6. doi: 10.4103/mtsp.mtsp_1_24.

[31] Hao M, Tan X, Liu K, Xin N. Nanoencapsulation of nutraceuticals: enhancing stability and bioavailability in functional foods. Front Nutr. 2026;12:1746176. doi: 10.3389/fnut.2025.1746176.

[32] Sethunga M, Rangani SC, Munaweera I, Ranaweera KKDS. Hybrid nanoencapsulation systems: integrating natural polymers with synthetic nanomaterials for enhanced delivery of bioactive compounds in functional foods. Nanoscale Adv. 2025;7(24):7867–90. doi: 10.1039/d5na00751h.

[33] Siraj A, Naqash F, Shah MA, Fayaz S, Majid D, *et al*. Nanoemulsions: formation, stability and an account of dietary polyphenol encapsulation. Int J Food Sci Technol. 2021;56(9):4193–205. doi: 10.1111/ijfs.15228.

[34] Jampilek J, Kralova K. Potential of nanonutraceuticals in increasing immunity. Nanomaterials. 2020;10(11):2224. doi: 10.3390/nano10112224.

[35] European Commission. Nanomaterials in food [Internet]. Brussels: European Commission; 2025 [cited 2026 Feb 10]. Available from: https://food.ec.europa.eu/food-safety/novel-food/nanomaterials_en

[36] Sohal IS, O'Fallon KS, Gaines P, Demokritou P, Bello D. Ingested engineered nanomaterials: state of science in nanotoxicity testing and future research needs. Part Fibre Toxicol. 2018;15(1):29. doi: 10.1186/s12989-018-0265-1.

[37] Drew R, Hagen T. Potential health risks associated with nanotechnologies in existing food additives. Melbourne: ToxConsult Pty Ltd; 2016.

[38] Grieger KD, Hansen SF, Mortensen NP, Cates S, Kowalcyk B. International implications of labeling foods containing engineered nanomaterials. J Food Prot. 2016;79(5):830–42. doi: 10.4315/0362-028X.JFP-15-335.

[39] Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, *et al*. Guidance on risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain: Part 1, human and animal health. EFSA J. 2018;16(7):e05327. doi: 10.2903/j.efsa.2018.5327.

[40] Addressing food safety concerns and risks of nanomaterials in food [Internet]. [place unknown]: Food Safety Institute; 2025 May 14 [cited 2026 Feb 10]. Available from: https://foodsafety.institute/emerging-trends-food-technology-safety/food-safety-nanomaterials-risks/

[41] Yelmate AA, Doijode Prem, Comparative study of regulation of Medical Devices in different Countries, Journal of technology, 12(10) 2024, 1394-1407.

[42] Yelmate AA, Choure Virat, Review Article: A brief review on Drug Master file, journal of technology, 12(12), 2024, 1099-1113.